Evonik and Laxxon Medical Partnership Focus
Evonik Industries is proud of its history, with over one hundred and fifty years of experience in the chemical industry. Recently, Evonik Industries teamed up with Laxxon Medical to form a partnership that will ultimately lead to better pharmaceutical solutions for people worldwide.
How does Evonik Industry’s long-standing history of improving life through biotechnology work with Laxxon Medical’s innovative pharmaceutical solutions?
The History of Evonik Industries
Evonik Industries are considered to be a world leader when it comes to specialty chemicals, and that proud history began over 150 years ago with a variety of different companies. They are active in various sectors, including Nutrition and Care, Resource Efficiency, Performance Materials, Service, and other areas.
The Nutrition and Care sector produces various specialty chemicals that are primarily used in consumer goods for everyday needs, along with animal nutrition and other healthcare products.
Their Resource Efficiency sector supplies materials and specialty additives for environmentally friendly and energy-efficient system solutions for paints, coatings, automotive, construction materials, and adhesives.
The Performance Materials sector focuses on manufacturing polymer materials and intermediates for the plastics, rubber, and agricultural industries.
Their Services sector focuses on on-site management, waste management, technical, utilities, engineering, and logistics services.
As one of the world leaders in specialty chemicals, Evonik Industries is active in over 100 different companies worldwide and generated sales of over €15 billion with a profit of €2.38 billion in 2021.
Evonik Industries can trace its origins through several other companies with a history stretching back over one hundred years with operations based in various countries, including the United States.
With a strong focus on innovation and sustainability, Evonik Industries has been diversifying far beyond chemistry to create a range of profitable, innovative, and sustainable solutions for its customers.
Currently, Evonik Industries has over 33,000 employees, all working together to complete one common goal: They want to improve life today and tomorrow for generations to come, leaving the world in a better place.
Evonik Industries and Laxxon Medical – an Innovative Force
Laxxon’s patented 3D screen printing technology enables the controlled release of active pharmaceutical ingredients (APIs) within a single tablet. In addition, by utilizing Evonik’s specialized polymers, together, they can ensure the targeted delivery of active ingredients in the novel tablets.
It’s not just a financial arrangement. Laxxon Medical is conducting joint product development and cooperation together. For example, Evonik Industries will produce tablets utilizing Laxxon Medical’s 3D screen printing technology, and shortly, Laxxon will utilize Evonik Industries products in their printing pastes.
“This technology is great for patients. We expect fewer side effects from more controlled drug delivery and having fewer pills reduces the risk of forgetting doses during the day,” said Lutz Stoeber, head of Evonik Venture Capital North America. “We are pleased to support innovation that brings real benefits to people and their health.”
“Evonik is the perfect partner to support the development of novel tablets with unique release properties,” said Kerschbaumer, Chief Executive Officer of Laxxon Medical. “We are pleased to have one of the world’s leading specialty chemical companies at our side, with whom we can further develop our products while manufacturing them commercially.”
Further Development of Medicine
It’s not every day that two companies from vastly different sectors seem to fit together so integrally as Laxxon Medical and Evonik Industries. The duo can help pharmaceutical companies bring to market a range of drug products in complex oral dosage forms, including small molecules, peptides, enzymes, nucleic acids, and those with high-potency APIs and controlled substances.
We’re excited about what the future holds for both companies and, through joint research and development programs, what medicines can be developed, and 3D printed for stakeholders and, ultimately, people worldwide.
Laxxon Medical is dedicated to engineering patented 3D pharmaceutical solutions which optimize products and benefit patients. Our goal is to establish SPID®-Technology as a manufacturing process with the individual and the pharmaceutical partner in mind.